Cardiac gene expression profiling of heart failure treatment with the anti-ischemic drug ranolazine
- Other Publication
Heart failure is a leading cause of cardiovascular mortality with limited options for treatment. We analyzed whether the anti-ischemic drug ranolazine could retard the progression of heart failure in an experimental model of heart failure induced by 6 months of chronic pressure overload. The study showed that 2 months of ranolazine treatment improved cardiac function of aortic constricted C57BL/6J (B6) mice with symptoms of heart failure as assessed by echocardiography. The microarray gene expression study of heart tissue from failing hearts relative to ranolazine-treated and healthy control hearts identified heart failure-specific genes that were normalized during treatment with the anti-ischemic drug ranolazine Show more
External linksFull text via SFX
PublisherNCBI GEO database
Organisational unit03735 - Quitterer, Ursula M.
MoreShow all metadata